View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 11, 2021

AbbVie and Caribou enter $340m deal to develop CAR-T cell therapies

AbbVie has signed a collaboration and licensing agreement with Caribou Biosciences for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics.

AbbVie has signed a collaboration and licensing agreement with Caribou Biosciences for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics.

Even though allogeneic, ‘off-the-shelf’ CAR-T cell therapies demonstrated early promise in some cancer patients and there exists a need for overcoming the allogeneic CAR-T cell rejection by the host immune system.

Using Caribou’s CRISPR genome editing platform to engineer CAR-T cells to withstand host immune attack would aid in developing the next-generation of ‘off-the-shelf’ cellular therapies to benefit a wider population of patients.

Under the agreement, AbbVie will carry out research and development of two new CAR-T cell therapies directed to targets specified by the company, by leveraging Caribou’s next-generation Cas12a CRISPR hybrid RNA-DNA (chRDNA) genome editing and cell therapy technologies.

AbbVie will have exclusive rights to the Caribou’s genome editing and cell therapy technologies for the selected targets.

For the collaboration programmes, Caribou will carry out specific pre-clinical research, development and manufacturing activities and AbbVie will reimburse Caribou for all activities under the partnership.

As per the deal, AbbVie is in charge of all clinical development, commercialisation and manufacturing. It also holds an option to pay a fee to expand the partnership to include up to two more CAR-T cell therapies.

In this regard, Caribou will get a $40m upfront cash payment and equity investment, as well as up to $300m as future development, regulatory and launch milestones.

It may also receive additional payments for commercial milestones and global tiered royalties.

Caribou Biosciences president and CEO Rachel Haurwitz said: “This collaboration validates Caribou’s differentiated next-generation CRISPR genome editing technologies that provide best-in-class efficiency and specificity.

“Genome-edited CAR-T cell therapies hold tremendous potential for patients, and this partnership accelerates our ability to address significant unmet medical need.”

Meanwhile, the US Food and Drug Administration (FDA) has approved AbbVie company Allergan’s BOTOX for treating detrusor (bladder muscle) overactivity linked to a neurologic condition in paediatric patients aged five years and above.

The approval derives from data of a Phase III study, which showed that intradetrusor administration of BOTOX 200 Units reduced daytime urinary incontinence episodes and decreased maximum bladder pressure and increased bladder capacity at week six.

Last September, AbbVie entered a global collaboration agreement with I-Mab to develop and commercialise lemzoparlimab (TJC4), an immuno-oncology therapy.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology